Mitigation of pennyroyal oil hepatotoxicity in the mouse

Academic Emergency Medicine

Volumn 10, Issue 10, 2003, Pages 1024-1028

  Sztajnkrycer, Matthew D ^a,b,d   Otten, Edward J ^a,b   Bond, G Randall ^b   Lindsell, Christopher J ^b,c   Goetz, Robert J ^a  

^a Cincinnati Drug and Poison Information Center   (United States)

^b Department of Emergency Medicine ^*  (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Basic science; Cytochrome P450; Hepatotoxicity; Mouse; Pennyroyal

Indexed keywords

ALANINE AMINOTRANSFERASE; CIMETIDINE; CORN OIL; CYCLOHEXANONE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 2E1; DIMETHYL SULFOXIDE; DISULFIRAM; ENZYME INHIBITOR; ESSENTIAL OIL; HISTAMINE H2 RECEPTOR ANTAGONIST; PENNYROYAL OIL; PLANT EXTRACT; PULEGONE; TERPENE; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL; ANIMAL MODEL; ARTICLE; BIOTRANSFORMATION; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HEDEOMA; LIVER DISEASE; LIVER FUNCTION; LIVER TOXICITY; MENTHA PULEGIUM; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL;

EID: 0141445989     PISSN: 10696563     EISSN: None     Source Type: Journal    
DOI: 10.1197/S1069-6563(03)00337-3     Document Type: Article

References (25)

1. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993; 328:246-52.
2. Huxtable RJ. The myth of beneficent nature: the risks of herbal preparations. Ann Intern Med. 1992; 117:165-6.
3. Burns MM. Alternative medicine: herbal preparations. Clin Pediatr Emerg Med. 2000; 1:186-90.
4. Tomlinson B, Chan TYK, Chan JCN, Critchley JAJH, But PPH. Toxicity of complementary therapies: an eastern perspective. J Clin Pharmacol. 2000; 40:451-6.
5. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med. 1996; 124:726-34.
6. Vadiraja BB, Gaikwad NW, Madyastha KM. Hepatoprotective effect of C-phycocyanin: protection for carbon tetrachloride and R-(+)-pulegone-mediated hepatotoxicity in rats. Biochem Biophys Res Commun. 1998; 249:428-31.
7. Carmichael PG. Pennyroyal metabolites in human poisoning. Ann Intern Med. 1997; 126:250-1.
8. Buechel DW, Haverlah VC, Gardner ME. Pennyroyal oil ingestion: report of a case. J Am Osteopath Assoc. 1983; 82:793-4.
9. Netland KE, Martinez J. Abortifacients: toxidromes, ancient to modern - a case series and review of the literature. Acad Emerg Med. 2000; 7:824-9.
10. Gordon WP, Huitric AC, Seth CL, McLanahan RH, Nelson SD. The metabolism of the abortifacient terpene, (R)-(+)-pulegone, to a proximate toxin, menthofuran. Drug Metab Dispos. 1987; 15:589-94.
11. Thomassen D, Slattery JT, Nelson SD. Menthofuran-dependent and independent aspects of pulegone hepatotoxicity: roles of glutathione. J Pharmacol Exp Ther. 1990; 253:567-72.
12. Gordon WP, Forte AJ, McMurtry RJ, Gal J, Nelson SD. Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse. Toxicol Appl Pharmacol. 1982; 65:413-24.
13. Bakerink JA, Gospe SM, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics. 1996; 98:944-7.
14. Graham K. Pennyroyal. In: Dart RC, Hurlburt KM, Kuffner EK, Yip L (eds). The 5 Minute Toxicology Consult. Philadelphia, PA: Lippincott Williams & Wilkins, 2000, pp 560-1.
15. Khojasteh-Bakht SC, Chen W, Koenigs LL, Peter RM, Nelson SD. Metabolism of (R)-(+)-pulegone and (R)-(+)-menthofuran by human liver cytochrome P-450s: evidence for formation of a furan epoxide. Drug Metab Dispos. 1999; 27:574-80.
16. Sullivan JB, Rumack BH, Thomas H, Peterson RG, Bryson P. Pennyroyal oil poisoning and hepatotoxicity. JAMA. 1979; 26:2873-4.
17. Thomassen D, Slattery JT, Nelson SD. Contribution of menthofuran to the hepatotoxicity of pulegone: assessment based on matched area under the curve and on matched time course. J Pharmacol Exp Ther. 1988; 244:825-9.
18. Mizutani T, Nomura H, Nakanishi K, Fujita S. Effects of drug metabolism modifiers on pulegone-induced hepatotoxicity in mice. Res Commun Chem Pathol Pharmacol. 1987; 58:75-83.
19. Howland MA. Pharmacokinetic and toxicokinetic principles. In: Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS (eds). Goldfrank's Toxicologic Emergencies, 7th Edition. New York, NY: McGraw-Hill, 2002, pp 166-85.
20. Parkinson A. Biotransformation of xenobiotics. In: Klaassen CD (ed). Casarett & Doull's Toxicology: The Basic Science of Poisons, 5th Edition. New York, NY: McGraw-Hill, 1996, pp 113-86.
21. Rudd GD, Donn KH, Grisham JW. Prevention of acetaminophen-induced hepatic necrosis by cimetidine in mice. Res Comm Chem Pathol Pharmacol. 1981; 32:369-72.
22. Al-Mustafa ZH, Al-Ali AK, Qaw FS, Abdul-Cader Z. Cimetidine enhances the hepatoprotective action of N-acetylcysteine in mice treated with toxic doses of paracetamol. Toxicology. 1997; 121:223-8.
23. Burkhart KK, Janco N, Kulig KW, Rumack BH. Cimetidine as adjunctive treatment for acetaminophen overdose. Hum Exp Toxicol. 1995; 14:299-304.
24. Hazai E, Vereczkey L, Montostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem Biophys Res Commun. 2002; 291:1089-94.
25. Manyike PT, Kharasch ED, Kalhom TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000; 67:275-82.